| 000 | 01829 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517151632.0 | ||
| 264 | 0 | _c20180523 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1873-5010 | ||
| 024 | 7 |
_a10.1016/j.jcf.2017.04.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVanDevanter, D R | |
| 245 | 0 | 0 |
_aRationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. _h[electronic resource] |
| 260 |
_bJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _c09 2017 |
||
| 300 |
_a607-615 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aClinical Protocols _xstandards |
| 650 | 0 | 4 |
_aCystic Fibrosis _xcomplications |
| 650 | 0 | 4 |
_aEndpoint Determination _xmethods |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aForced Expiratory Volume _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOutcome Assessment, Health Care _xmethods |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xmethods |
| 650 | 0 | 4 |
_aRespiratory Tract Infections _xdrug therapy |
| 650 | 0 | 4 | _aSample Size |
| 650 | 0 | 4 |
_aSurveys and Questionnaires _xstandards |
| 650 | 0 | 4 | _aSymptom Flare Up |
| 700 | 1 | _aHeltshe, S L | |
| 700 | 1 | _aSpahr, J | |
| 700 | 1 | _aBeckett, V V | |
| 700 | 1 | _aDaines, C L | |
| 700 | 1 | _aDasenbrook, E C | |
| 700 | 1 | _aGibson, R L | |
| 700 | 1 | _aRaksha, Jain | |
| 700 | 1 | _aSanders, D B | |
| 700 | 1 | _aGoss, C H | |
| 700 | 1 | _aFlume, P A | |
| 773 | 0 |
_tJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society _gvol. 16 _gno. 5 _gp. 607-615 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jcf.2017.04.004 _zAvailable from publisher's website |
| 999 |
_c27109183 _d27109183 |
||